Stefan Weber

09.01.2025 • News

Newron Licenses Evenamide to Myung In Pharm

Newron Pharmaceuticals, a central nervous system (CNS) focused biopharmaceutical company, and Myung In Pharm, South Korea’s leading CNS pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture, and commercialize Newron’s schizophrenia treatment evenamide.

Top-Feature

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

Interview

Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Myung in Pharm